针对性抗炎纳米酶具有亲血管性活性,用于心肌梗塞治疗
Wenling Yang1,2,3,4, Xuelian Li1,2,3,4, Jie Lei5,6
1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Advanced healthcare materials
|April 30, 2025
概括
这项研究引入了一种新型纳米粒子 (PNP@Nb2C-MSN),可以在心肌梗塞 (MI) 后有效清除活性氧物种 (ROS). 这种治疗可以通过减少炎症和促进心脏梗塞的愈合来改善心脏功能.
科学领域:
- 生物医学工程 生物医学工程
- 心血管研究研究心血管研究
- 纳米医学是一种纳米医学.
背景情况:
- 心肌梗塞 (MI) 引起显著的氧化损伤和自功能障碍,由于反应性氧物种 (ROS).
- 目前的MI治疗重点是重血管化,但往往忽视了早期的ROS清理.
- 有效的ROS清除对于抑制MI进展和恢复心脏功能至关重要.
研究的目的:
- 开发和评估一种可响应ROS的仿生纳米粒子 (PNP@Nb2C-MSN),用于治疗心肌梗塞.
- 为了研究纳米颗粒能够清理ROS,促进血管生成,减少炎症和增强心脏病发作中的自性.
主要方法:
- 通过将碳化物MXenes (Nb2C) 集成到被血小板膜覆盖的半孔纳米粒子 (MSN) 上,构建了对ROS敏感的仿生纳米粒子 (PNP@Nb2C-MSN).
- 在MI的急性阶段,静脉注射纳米颗粒,以向心脏梗塞的目标输送.
- 通过体外和体内研究评估纳米粒子疗效,评估ROS清理,血管生成,炎症 (NF-κB通路) 和自 (AMPK通路).
主要成果:
- PNP@Nb2C-MSN有效地清理了心脏病发作区域的多余ROS,抑制了氧化应激进展.
- 从MSN释放的离子促进了心脏病发作区域内的血管生成.
- 这些纳米颗粒降低了NF-κB通路 (减少炎症) 的调节,并激活了AMPK通路 (增强自),从而阻止了病理进展.
- 在体外和体外MI模型中证明了心脏功能的改善.
结论:
- PNP@Nb2C-MSN在心肌梗塞治疗中具有显著的治疗潜力.
- 仿生纳米粒子通过解决氧化应激和促进心脏修复,为早期心脏病干预提供了一个有希望的策略.
- 这种方法为改善心肌梗塞患者的治疗结果提供了一个新的途径.
相关概念视频
01:16Antianginal Drugs: Nitrates and β-Blockers
432
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
432
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
385
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385